Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pliant Therapeutics Inc
(NQ:
PLRX
)
14.70
+0.07 (+0.48%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pliant Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
9 Analysts Have This to Say About Pliant Therapeutics
March 10, 2023
Via
Benzinga
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
March 09, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
March 08, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
March 01, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Why Pliant Therapeutics Stock Is Skyrocketing This Week
January 26, 2023
The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.
Via
The Motley Fool
Expert Ratings for Pliant Therapeutics
January 23, 2023
Via
Benzinga
An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50%
January 23, 2023
The company has a potentially best-in-class approach to a lung condition.
Via
Investor's Business Daily
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
February 24, 2023
Via
Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Events
February 07, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
February 02, 2023
Phase 1 clinical study initiation expected in the second quarter of 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 27, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
January 25, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
January 25, 2023
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
Via
MarketBeat
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
January 24, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
January 23, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher
January 23, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. The...
Via
Benzinga
Dow, Nasdaq Boasting Triple-Digit Midday Lead
January 23, 2023
Investors seem intent on leaving last week's losses behind, as earnings season heats up.
Via
Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
January 23, 2023
Via
Benzinga
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 23, 2023
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its...
Via
Benzinga
Dow Jumps Over 300 Points; Crude Oil Up 1%
January 23, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday. The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500...
Via
Benzinga
Pliant Therapeutics (NASDAQ: PLRX) Reports Positive Phase 2 Clinical Trial Data of Bexotegrast in Treatment of Idiopathic Pulmonary Fibrosis
January 23, 2023
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
Via
Spotlight Growth
US Stocks Mostly Higher; Synchrony Financial Earnings Top Views
January 23, 2023
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 90 points on Monday.
Via
Benzinga
Why Is Xylem (XYL) Stock Down 9% Today
January 23, 2023
Xylem (XYL) stock is slipping on Monday after the company revealed plans to acquire Evoqua (AQUA) in a $7.5 billion deal.
Via
InvestorPlace
Why Is Ryvyl (RVYL) Stock Is On the Move Today?
January 23, 2023
Ryvyl (RVYL) stock is on the move Monday after saying its prior financial data can no longer be relied on and revealing an investigation.
Via
InvestorPlace
Benzinga's Talk of the Town: Top Social Trending Stories You Need To Know
January 23, 2023
What's trending on Social Media today:
Via
Benzinga
Why Is Pliant Therapeutics (PLRX) Stock Up 62% Today?
January 23, 2023
Pliant Therapeutics (PLRX) stock is taking off on Monday after releasing positive Phase 2a clinical trial data for bexotegrast.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 23, 2023
Via
Benzinga
Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
January 23, 2023
Gainers Jeffs' Brands Ltd (NASDAQ: JFBR) rose 76.5% to $2.70 in pre-market trading after jumping 19% on Friday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 23, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers traders will want to watch for Monday!
Via
InvestorPlace
Pliant Therapeutics Stock Surges After Positive Data From Lead Program In Scarred Lung Disorder
January 23, 2023
Pliant Therapeutics Inc (NASDAQ: PLRX) has announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.